Greater Manchester has announced that it is to showcase the region’s thriving biotechnology sector at the industry’s leading conference, BIO International Convention in California later this month. The Manchester delegation will be headed up by representatives from MIDAS, Manchester’s inward investment agency and the NorthWest EHealth (NWEH) partnership.
The exhibition, which takes place at the San Diego Conference Centre, in San Diego from 23-26 June 2014, is the largest, most influential biotech meeting in the world, offering four days of network and learning opportunities — from sessions and speciality forums, to networking events covering 17 industry topics, plus there are over 1,700 exhibitors.
Manchester will be exhibiting on the UKTI Pavilion on stand 3317. Delegates to the stand will have the opportunity to access a wide range of information about the region’s bio and life science work happening in city, as well as having the opportunity to speak with NWEH and MIDAS about Manchester’s offer for the industry. There will also be ongoing demos of a pioneering diagnostic system.
Manchester will also be involved in a panel debate discussing a ‘world first’ the Salford Lung Study. The Study, which is taking place in Greater Manchester, is the first time a prospective real-world trial of its size and scope has been conducted. The Panel discussion will be held on Thursday 26 June between 14:15 and 15:30 (Room 31A, panel session 2433) with Professor Martin Gibson, Chief Executive NWEH, Associate Director for Industry NIHR CCRN and Research and Informatics, Director Greater Manchester AHSN. He will be joined by collaborators from industry and academia working in bio and life sciences.
Tim Newns, chief executive at MIDAS, said: “Greater Manchester is renowned for its innovation. From the splitting of the atom, the first modern computer, the first hip replacement, to the first test tube baby, the discovery of Graphene and the Salford Lung Study– Greater Manchester is a region of medical and technology pioneers.
“The concept of highly connected urban science parks linked with academia, the NHS and excellent connectivity, coupled with our digital infrastructure and fully e-enabled health trust, provides a winning formula for business innovation and investment. This is enabling the city to gain recognition as a top location for biomedical companies around the world. We’re delighted to be part of this prestigious international forum and we look forward to showcasing the region, in partnership with NWEH, as a top location for biotechnology and life sciences companies around the world.”
Professor Martin Gibson, CEO at NorthWest EHealth, added: “NWEH benefits greatly from its location in Manchester and its strong relationship with the other elements of the health eco-system and digital economy. The unique set of circumstances has attracted a lot of interest from industry, for example GlaxoSmithKline (Salford Lung Study) have come to work with us to get the benefits of the integrated systems. We have established an understanding with Hitachi who has set up its big data laboratory in Manchester partly because we and our partner organisations have the resources to help them in the healthcare sector, our close working relationships with all these organisations and the city’s big data initiatives.”
Manchester is a city that committed to open data and is the only UK city to take part in City SDK, a €3.4 million scheme that is creating a toolkit for the development of digital services within cities.